| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 5.4K | 4.6% | 7.5% |
| Total Income | 5.4K | 4.6% | 7.5% |
| Expenditure | 4.3K | 4.0% | 0.5% |
| PBT | 1.1K | 8.8% | 12.7% |
| Net Profit | 907.00 | 32.4% | 13.8% |
| OPM | 21.65% | 0.48pp | 5.46pp |
| NPM | 16.67% | 9.11pp | 0.92pp |
| EPS | 0.62 | 31.1% | 14.8% |
Boston Scientific Reports Q2 2026 Results with 7.5% Net Sales Growth
29 Jul 2026 · 29 Jul, 4:06 pm
Summary
Boston Scientific announced strong second quarter 2026 financial results, with net sales reaching $5.442 billion, a 7.5 percent increase on a reported basis and 7.0 percent on an organic basis year-over-year. GAAP net income attributable to common stockholders was $907 million, or $0.61 per share, up from $797 million, or $0.53 per share, in the prior year. Adjusted EPS also saw a significant increase to $0.86 from $0.75. Management expressed confidence in the company's long-term growth, driven by disciplined execution and strategic investments in high-impact opportunities.
Key Highlights
- 1
Boston Scientific generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis compared to the prior year period.
- 2
The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share, compared to $797 million or $0.53 per share a year ago.
- 3
Adjusted EPS for the second quarter of 2026 was $0.86 per share, an increase from $0.75 per share in the prior year period.
- 4
MedSurg segment net sales increased by 5.9 percent on a reported basis, while Cardiovascular segment net sales grew by 8.3 percent on a reported basis compared to the prior year.
- 5
The company completed a $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
- 6
Boston Scientific invested $1.5 billion in MiRus LLC, securing an equity stake and an exclusive option to acquire the MiRus TAVR business.
- 7
Clinical trial results for the FARAPULSE Pulsed Field Ablation (PFA) system met all safety and effectiveness endpoints, demonstrating statistical superiority over anti-arrhythmic drugs.
Management Comments
Mike Mahoney
Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.
Informational and educational content only. Not investment advice.